Leerink Partners downgrades Gilead Sciences to Market Perform

0 min read | Published on 22 Jul 2026, 01:10 AM |Updated on 22 Jul 2026, 01:10 AM

Reviewed by

Radhika SScanX News Team

Key Highlights

Leerink Partners analyst Daina Graybosch downgraded Gilead Sciences from Outperform to Market Perform and lowered the price target to $127 from $146.

*this image is generated using AI for illustrative purposes only.

Leerink Partners analyst Daina Graybosch downgraded Gilead Sciences from Outperform to Market Perform and lowered the price target to $127 from $146. The revision reflects a revised outlook on the company's stock performance.

Rating and Price Target Changes

The downgrade moves Gilead Sciences to a Market Perform rating from its previous Outperform status. Concurrently, the price target was reduced by $19.

Metric	Previous	New
Rating	Outperform	Market Perform
Price Target	$146	$127

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors led Leerink Partners to revise Gilead Sciences' stock outlook?

How might this downgrade impact investor sentiment toward Gilead Sciences in the short term?

Are there upcoming clinical trial results or regulatory decisions that could influence Gilead's future performance?

Gilead Sciences returns 11.43% annually over 20 years

0 min read | Published on 21 Jul 2026, 04:38 AM |Updated on 21 Jul 2026, 04:38 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Gilead Sciences has outperformed the market with an average annual return of 11.43% over the last two decades. The company's current market capitalization stands at $164.76 billion. A hypothetical $100 investment made 20 years ago would now be worth $854.46.

*this image is generated using AI for illustrative purposes only.

Gilead Sciences has generated an average annual return of 11.43% over the past 20 years, outperforming the market by 2.19% on an annualized basis. The biopharmaceutical company currently commands a market capitalization of $164.76 billion. This long-term performance highlights the impact of compounded returns on equity growth over extended periods.

Investment Growth Analysis

If an investor had purchased $100 worth of Gilead Sciences stock 20 years ago, that investment would be valued at $854.46 today. This calculation is based on a current share price of $132.70. The substantial growth underscores the potential benefits of long-term holding strategies in the healthcare sector.

Key Performance Metrics

The following table summarizes the financial performance data for Gilead Sciences over the specified period:

Metric	Value
Average Annual Return	11.43%
Market Outperformance	2.19%
Current Market Capitalization	$164.76 billion
Current Share Price	$132.70
Value of $100 Invested 20 Years Ago	$854.46

The data illustrates how consistent returns can significantly multiply initial capital over time, emphasizing the importance of compounded growth in investment portfolios.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Can Gilead maintain its historical 11.43% annual return given current patent cliffs and pipeline risks?

How might upcoming regulatory changes impact the company's ability to sustain market outperformance?

What role will mergers and acquisitions play in driving future growth for Gilead?